Divis Laboratories Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zcv0ek5npycic5bp65fteha5.pdf

Key Takeaways


Custom Synthesis: The Quarter's Miss and the Multi-Year Bet

Dr. Murali K. Divi: "Actually, in fact, our Custom Synthesis business looked very optimistic and probably much better than any given time."

Margin Resilience and the Backward Integration Moat

Dr. Murali K. Divi: "If we did not take up the backward integration, had we been totally dependent on the supply for the raw material from China with increased prices anywhere from 20% to 40%, it would have troubled us in even staying in business."

Generic API: Pricing Pain, Potential Competitor Exit Gain

Dr. Murali K. Divi: "The price pressures still are there. You know the two big pharmas who are our competitors, I think for them, it is not very far from, at least one of them going to be what we hear is that they may be leaving. In such a case, probably we will have a large chunk shifting to our side as we already expanded, and we have plans to expand further."

Contrast Media: A New Growth Vector Takes Shape


Capacity, Capex, and the Kakinada Waiting Game


Nutraceuticals and Other Moving Parts

Dr. Murali K. Divi: "I think we have been always saying that we should not be looked at as on quarter-on-quarter basis. It is very difficult, either in the generic or in the Custom Synthesis to look at quarter-on-quarter basis."

Guidance & Commitments

CommitmentSpecificsTimeline
New custom synthesis opportunities begin yieldingQualifications, secondary-site formulation qualification, then commercial volumes start4 to 6 quarters
Fast-track phase 3 projects begin yieldingTwo fast-track projects expected to start contributingFY24
Patent-expiry generic API launchesDMFs filed, customer qualifications underway for drugs going off-patent2023 to 2025
Kakinada government clearance decisionWaiting for final state government clearance; all other clearances obtained6 to 9 months
Kakinada construction to commercial outputConstruction within 1 year, results from second year, full qualification thereafter2 to 3 years from approval
Margin pressures persist near-termSame margin pressures likely in immediate quarters before new opportunities lift growth1 to 2 quarters
MRI contrast media entrySample approvals, then qualifications; processes developed, discussions with leaders underway"Will take more time"

Key Metrics

MetricQ2 FY23
Consolidated total revenue₹1,935 cr, vs ₹2,007 cr in Q1 FY23
Profit after tax (PAT)₹494 cr
Profit before tax (PBT)₹615 cr
EBITDA margin36%, vs 38.5% for H1 FY23
Constant currency growthnegative 13%, vs negative 2% for H1 FY23
Forex gain₹31 cr, vs ₹87 cr for H1 FY23
Exports as % of revenue87%
Exports to US and Europe as % of revenue68%, vs 71% for H1 FY23
Product mix: generics vs custom synthesis57% / 43%, vs 52% / 48% for H1 FY23
Nutraceutical business revenue₹163 cr, vs ₹350 cr for H1 FY23
Capacity utilization80%–83%
Nutraceutical capacity utilization~80%
Capitalized assets during the quarter₹89 cr, vs ₹200 cr for H1 FY23
Capital work in progress₹542 cr as of 30 Sep 2022
Cash on books₹3,336 cr as of 30 Sep 2022
Receivables₹1,840 cr as of 30 Sep 2022
Inventories₹2,970 cr as of 30 Sep 2022
Dependency on China for raw materialsreduced by 20% in H1 FY23 vs H1 FY22